Clinical Trial Update: A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and pharmacodynamics of Dalazatide (ShK-186) over 4 weeks in adults with active plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Dalazatide (ShK-186) (ShK-186)

Snippet

Sponsor: Kineta Inc. | Conditions: Plaque Psoriasis | Phase 1 | Status: COMPLETED